ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL1201506
CHEMBL1201506
Compound Name GEMTUZUMAB OZOGAMICIN
ChEMBL Synonyms GEMTUZUMAB OZOGAMICIN | CMA-676 | MYLOTARG | CMC-676 | CDP-771 | WAY-CMA-676
Max Phase 4 (Approved)
Withdrawn Yes
Trade Names MYLOTARG

Sources

  • Clinical Candidates
  • Orange Book
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification
  • Withdrawn Drugs

Molecule Features

CHEMBL1201506 compound icon
Drug Type:Antibody Rule of Five:N First In Class:N Chirality:Single Stereoisomer Prodrug:N Oral:N Parenteral:Y Topical:N Black Box:Y Availability Type:Withdrawn

Withdrawal Information

Year 2010
Country United States
Reason The trial was stopped early when no improvement in clinical benefit was observed, and after a greater number of deaths occurred in the group of patients who received Mylotarg compared with those receiving chemotherapy alone
Class

Mechanism of Action

Mechanism of Action ChEMBL Target References
DNA inhibitor DNA FDA
Myeloid cell surface antigen CD33 binding agent Myeloid cell surface antigen CD33 FDA

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Leukemia, Lymphocytic, Chronic, B-CellD015451EFO:0000095chronic lymphocytic leukemia1ClinicalTrials
Leukemia, Promyelocytic, AcuteD015473EFO:0000224acute promyelocytic leukemia2ClinicalTrials
LeukemiaD007938EFO:0000565leukemia3ClinicalTrials
Leukemia, Myelomonocytic, JuvenileD054429EFO:1000309Juvenile Myelomonocytic Leukemia1ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-LymphomaD054198EFO:0000220acute lymphoblastic leukemia2ClinicalTrials
Myelodysplastic SyndromesD009190EFO:0000198myelodysplastic syndrome3ClinicalTrials
Leukemia, Myeloid, AcuteD015470EFO:0000222acute myeloid leukemia3ClinicalTrials
NeoplasmsD009369EFO:0000616neoplasm4ATC

Clinical Data

ClinicalTrials.gov GEMTUZUMAB OZOGAMICIN
The Cochrane Collaboration GEMTUZUMAB OZOGAMICIN

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Compound Cross References

ATC L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 - ANTINEOPLASTIC AGENTS
L01X - OTHER ANTINEOPLASTIC AGENTS
L01XC - Monoclonal antibodies
L01XC05 - gemtuzumab ozogamicin

ChemSpider ChemSpider Identifier not yet assigned
DailyMed gemtuzumab ozogamicin
Wikipedia Gemtuzumab_ozogamicin
spacer
spacer